These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 15792257)

  • 21. In vitro efficacy of antimicrobial agents against high-inoculum or biofilm-embedded meticillin-resistant Staphylococcus aureus with vancomycin minimal inhibitory concentrations equal to 2 μg/mL (VA2-MRSA).
    Tang HJ; Chen CC; Ko WC; Yu WL; Chiang SR; Chuang YC
    Int J Antimicrob Agents; 2011 Jul; 38(1):46-51. PubMed ID: 21549575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains.
    Bernard L; Vaudaux P; Rohner P; Huggler E; Armanet M; Pittet D; Lew DP; Schrenzel J
    J Microbiol Methods; 2004 May; 57(2):231-9. PubMed ID: 15063063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients.
    Wilson AP; Cepeda JA; Hayman S; Whitehouse T; Singer M; Bellingan G
    J Antimicrob Chemother; 2006 Aug; 58(2):470-3. PubMed ID: 16735420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.
    Kaplan SL; Afghani B; Lopez P; Wu E; Fleishaker D; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S178-85. PubMed ID: 14520144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prospective study of Staphylococcus aureus with reduced susceptibility to glycopeptides].
    Cantón R; Mir N; Martínez-Ferrer M; Sánchez del Saz B; Soler I; Baquero F
    Rev Esp Quimioter; 1999 Mar; 12(1):48-53. PubMed ID: 10896469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
    Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing therapy for MRSA pneumonia.
    Skrupky LP; Micek ST; Kollef MH
    Semin Respir Crit Care Med; 2007 Dec; 28(6):615-23. PubMed ID: 18095225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro susceptibility of staphylococci to linezolid and other antimicrobial agents.
    Poiată A; Tuchiluş C; Bădicuţ I; Grigore L; Buiuc D
    Roum Arch Microbiol Immunol; 2002; 61(4):293-9. PubMed ID: 15055263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
    Harper T; Miller D; Flynn HW
    Ophthalmology; 2007 May; 114(5):871-5. PubMed ID: 17383732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
    Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
    Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method.
    Abb J
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):319-21. PubMed ID: 12151194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
    Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
    Ross JE; Anderegg TR; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 May; 52(1):53-8. PubMed ID: 15878443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activities of 28 antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) from a clinical setting in Malaysia.
    Neela V; Sasikumar M; Ghaznavi GR; Zamberi S; Mariana S
    Southeast Asian J Trop Med Public Health; 2008 Sep; 39(5):885-92. PubMed ID: 19058585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.
    Maclayton DO; Hall RG
    Ann Pharmacother; 2007 Feb; 41(2):235-44. PubMed ID: 17299012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci.
    Betriu C; Redondo M; Boloix A; Gómez M; Culebras E; Picazo JJ
    J Antimicrob Chemother; 2001 Dec; 48(6):911-3. PubMed ID: 11733478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus.
    Sahuquillo Arce JM; Colombo Gainza E; Gil Brusola A; Ortiz Estévez R; Cantón E; Gobernado M
    Rev Esp Quimioter; 2006 Sep; 19(3):252-7. PubMed ID: 17099793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals.
    Cartolano GL; Cheron M; Benabid D; Leneveu M; Boisivon A;
    Clin Microbiol Infect; 2004 May; 10(5):448-51. PubMed ID: 15113324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.